Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyse...

por Grothey, Axel, Yoshino, Takayuki, Bodoky, Gyorgy, Ciuleanu, Tudor, Garcia-Carbonero, Rocio, García-Alfonso, Pilar, Van Cutsem, Eric, Muro, Kei, Mytelka, Daniel S, Li, Li, Lipkovich, Olga, Hsu, Yanzhi, Sashegyi, Andreas, Ferry, David, Nasroulah, Federico, Tabernero, Josep
Publicado 2018

Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials

por Zhu, Andrew X, Nipp, Ryan D, Finn, Richard S, Galle, Peter R, Llovet, Josep M, Blanc, Jean-Frederic, Okusaka, Takuji, Chau, Ian, Cella, David, Girvan, Allicia, Gable, Jonathon, Bowman, Lee, Wang, Chunxiao, Hsu, Yanzhi, Abada, Paolo B, Kudo, Masatoshi
Publicado 2020

Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data

por Fuchs, Charles S., Muro, Kei, Tomasek, Jiri, Van Cutsem, Eric, Cho, Jae Yong, Oh, Sang-Cheul, Safran, Howard, Bodoky, György, Chau, Ian, Shimada, Yasuhiro, Al-Batran, Salah-Eddin, Passalacqua, Rodolfo, Ohtsu, Atsushi, Emig, Michael, Ferry, David, Chandrawansa, Kumari, Hsu, Yanzhi, Sashegyi, Andreas, Liepa, Astra M., Wilke, Hansjochen
Publicado 2017

Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study

por Chau, Ian, Park, Joon Oh, Ryoo, Baek-Yeol, Yen, Chia-Jui, Poon, Ronnie, Pastorelli, Davide, Blanc, Jean-Frédéric, Kudo, Masatoshi, Pfiffer, Tulio, Hatano, Etsuro, Chung, Hyun Cheol, Kopeckova, Katerina, Phelip, Jean-Marc, Brandi, Giovanni, Ohkawa, Shinichi, Li, Chung-Pin, Okusaka, Takuji, Hsu, Yanzhi, Abada, Paolo B., Zhu, Andrew X.
Publicado 2018

Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab

por Zhu, Andrew X., Finn, Richard S., Kang, Yoon-Koo, Yen, Chia-Jui, Galle, Peter R., Llovet, Josep M., Assenat, Eric, Brandi, Giovanni, Motomura, Kenta, Ohno, Izumi, Daniele, Bruno, Vogel, Arndt, Yamashita, Tatsuya, Hsu, Chih-Hung, Gerken, Guido, Bilbruck, John, Hsu, Yanzhi, Liang, Kun, Widau, Ryan C., Wang, Chunxiao, Abada, Paolo, Kudo, Masatoshi
Publicado 2021

Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies

por Davids, Matthew S., O’Connor, Owen A., Jurczak, Wojciech, Samaniego, Felipe, Fenske, Timothy S., Zinzani, Pier Luigi, Patel, Manish R., Ghosh, Nilanjan, Cheson, Bruce D., Derenzini, Enrico, Brander, Danielle M., Reeves, James A., Knopińska-Posłuszny, Wanda, Allan, John N., Phillips, Tycel, Caimi, Paolo F., Lech-Maranda, Ewa, Burke, John M., Agajanian, Richy, Pettengell, Ruth, Leslie, Lori A., Cheah, Chan Y., Fonseca, Gustavo, Essell, James, Chavez, Julio C., Pagel, John M., Sharman, Jeff P., Hsu, Yanzhi, Miskin, Hari P., Sportelli, Peter, Weiss, Michael S., Flinn, Ian W.
Publicado 2021